公开(公告)号：WO2008021451A2

公开(公告)日：2008-02-21

申请号：PCT/US2007/018176

申请日：2007-08-14

Applicant: AKTIV-DRY LLC ,  SIEVERS, Robert, E. ,  BEST, Jessica, A. ,  CAPE, Stephen, P.

Inventor： SIEVERS, Robert, E. ,  BEST, Jessica, A. ,  CAPE, Stephen, P.

IPC: A61M15/00

CPC classification number: A61M15/00 ,  A61K9/0075 ,  A61K9/1623 ,  A61K9/1652 ,  A61M11/003 ,  A61M11/008 ,  A61M15/0086 ,  A61M15/0088 ,  A61M16/0078 ,  A61M16/0084 ,  A61M16/0093 ,  A61M16/1055 ,  A61M16/1065 ,  A61M2202/064

Abstract: In one embodiment, a human-powered dry powder inhaler comprises a human- powered compressible component operable to discharge an air pulse at an outlet at a pressure of about 1-40 psi; an inflatable reservoir operable to receive an air pulse discharged from the human-powered compressible component to provide an aerosol of a dry powder pharmaceutical formulation in the reservoir, the reservoir including an outlet valve; and a receiving mask in communication with the outlet valve and operable to receive an aerosol of dry powder from the reservoir and to deliver the aerosol to at least a mouth or nose of a patient. In another embodiment, the inhaler comprises a human-powered compressible component operable to discharge an air pulse at an outlet of a polymeric pressure release valve at a pressure of about 1-40 psi; and a receiving mask in communication with the outlet of the compressible component and operable to deliver an aerosol of dry powder to at least a mouth or nose of a patient. Methods for delivery of a dry powder pharmaceutical formulation to a patient are conducted in the absence of electrical power and circuitry and pre-pressurized propellant gas. Suitable dry powder pharmaceutical formulations may include myo-inositol and/or maltodextrin as a carrier and active ingredients such as vaccines or siRNA.

Abstract translation: 在一个实施例中，人力干粉吸入器包括人力动力可压缩部件，其可操作以在约1-40psi的压力下排出出口处的空气脉冲; 充气储存器，其可操作以接收从人力可压缩部件排出的空气脉冲，以在储存器中提供干粉末药物制剂的气溶胶，所述储存器包括出口阀; 以及与所述出口阀连通并且可操作以从所述储存器接收干燥粉末的气溶胶并将所述气溶胶输送到患者的至少一个口或鼻部的接收面罩。 在另一个实施例中，吸入器包括人力动力的可压缩部件，其可操作以在约1-40psi的压力下排出聚合物压力释放阀的出口处的空气脉冲; 以及接收面罩，其与所述可压缩部件的出口连通并且可操作以将干粉的气溶胶输送到患者的至少一个口或鼻部。 在没有电力和电路和预加压推进剂气体的情况下，将干粉药物制剂递送到患者的方法进行。 合适的干粉药物制剂可以包括肌醇和/或麦芽糖糊精作为载体和活性成分例如疫苗或siRNA。

公开(公告)号：WO2011133867A2

公开(公告)日：2011-10-27

申请号：PCT/US2011/033587

申请日：2011-04-22

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE ,  AKTIV-DRY LLC ,  SIEVERS, Robert ,  CAPE, Stephen ,  MCADAMS, David ,  MANION, J'aime ,  PATHAK, Pankaj

Inventor： SIEVERS, Robert ,  CAPE, Stephen ,  MCADAMS, David ,  MANION, J'aime ,  PATHAK, Pankaj

IPC: A61K31/6615 ,  A61K31/661 ,  A61K31/045 ,  A61K9/16 ,  A61K9/14 ,  A61K9/72 ,  A61K39/12 ,  A61P35/00

CPC classification number: A61K31/047 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/1647 ,  A61K9/1688 ,  A61K9/1694 ,  A61K9/5153 ,  A61K9/5192 ,  A61K39/12 ,  A61K39/165 ,  A61K45/06 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/544 ,  A61K2039/60 ,  C12N2760/18434 ,  A61K2300/00

Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.

Abstract translation: 用于治疗和/或延缓发育不良病变发作的方法和产品以及用于口服给药的晶片使用干粉组合物，包括肌醇。 向个体施用用于病毒或细菌的疫苗的方法包括通过一条途径向个体施用疫苗的第一部分，并通过第二种不同途径施用第二部分。 在具体实施例中，第一路线是舌下的。 疫苗以包含纳米颗粒和微粒的组合的干粉组合物的形式提供，或以小于约1分钟在室温下溶解于水中的晶片的形式提供。 疫苗的储存稳定单位剂量通过将包含疫苗和载体的干粉组合物的各单位剂量单独包装在由气体和防湿材料形成的泡罩室中来提供。

公开(公告)号：WO2011133867A3

公开(公告)日：2012-04-05

申请号：PCT/US2011033587

申请日：2011-04-22

Applicant: UNIV COLORADO REGENTS ,  AKTIV DRY LLC ,  SIEVERS ROBERT ,  CAPE STEPHEN ,  MCADAMS DAVID ,  MANION J AIME ,  PATHAK PANKAJ

Inventor： SIEVERS ROBERT ,  CAPE STEPHEN ,  MCADAMS DAVID ,  MANION J AIME ,  PATHAK PANKAJ

IPC: A61K31/6615 ,  A61K9/14 ,  A61K9/16 ,  A61K9/72 ,  A61K31/045 ,  A61K31/661 ,  A61K39/12 ,  A61P35/00

CPC classification number: A61K31/047 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/1647 ,  A61K9/1688 ,  A61K9/1694 ,  A61K9/5153 ,  A61K9/5192 ,  A61K39/12 ,  A61K39/165 ,  A61K45/06 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/544 ,  A61K2039/60 ,  C12N2760/18434 ,  A61K2300/00

Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.

Abstract translation: 用于治疗和/或延缓发育不良病变发作的方法和产品以及用于口服给药的晶片使用干粉组合物，包括肌醇。 向个体施用用于病毒或细菌的疫苗的方法包括通过一条途径向个体施用疫苗的第一部分，并通过第二种不同途径施用第二部分。 在具体实施例中，第一路线是舌下的。 疫苗以包含纳米颗粒和微粒的组合的干粉组合物的形式提供，或以小于约1分钟在室温下溶解于水中的晶片的形式提供。 疫苗的储存稳定单位剂量通过将包含疫苗和载体的干粉组合物的各单位剂量单独包装在由气体和防湿材料形成的泡罩室中来提供。

公开(公告)号：WO2008021451A3

公开(公告)日：2008-07-24

申请号：PCT/US2007018176

申请日：2007-08-14

Applicant: AKTIV DRY LLC ,  SIEVERS ROBERT E ,  BEST JESSICA A ,  CAPE STEPHEN P

Inventor： SIEVERS ROBERT E ,  BEST JESSICA A ,  CAPE STEPHEN P

IPC: A61M15/00 ,  A61K9/72

CPC classification number: A61M15/00 ,  A61K9/0075 ,  A61K9/1623 ,  A61K9/1652 ,  A61M11/003 ,  A61M11/008 ,  A61M15/0086 ,  A61M15/0088 ,  A61M16/0078 ,  A61M16/0084 ,  A61M16/0093 ,  A61M16/1055 ,  A61M16/1065 ,  A61M2202/064

Abstract: In one embodiment, a human-powered dry powder inhaler comprises a human- powered compressible component operable to discharge an air pulse at an outlet at a pressure of about 1-40 psi; an inflatable reservoir operable to receive an air pulse discharged from the human-powered compressible component to provide an aerosol of a dry powder pharmaceutical formulation in the reservoir, the reservoir including an outlet valve; and a receiving mask in communication with the outlet valve and operable to receive an aerosol of dry powder from the reservoir and to deliver the aerosol to at least a mouth or nose of a patient. In another embodiment, the inhaler comprises a human-powered compressible component operable to discharge an air pulse at an outlet of a polymeric pressure release valve at a pressure of about 1-40 psi; and a receiving mask in communication with the outlet of the compressible component and operable to deliver an aerosol of dry powder to at least a mouth or nose of a patient. Methods for delivery of a dry powder pharmaceutical formulation to a patient are conducted in the absence of electrical power and circuitry and pre-pressurized propellant gas. Suitable dry powder pharmaceutical formulations may include myo-inositol and/or maltodextrin as a carrier and active ingredients such as vaccines or siRNA.

Abstract translation: 在一个实施例中，人力干粉吸入器包括人力驱动的可压缩部件，其可操作以在约1-40psi的压力下在出口处排出空气脉冲; 可操作以接收从人力可压缩部件排出的空气脉冲以在储存器中提供干粉药物制剂的气雾剂的可膨胀储存器，所述储存器包括出口阀; 以及接收面罩，所述接收面罩与所述出口阀连通并且可操作以接收来自所述储存器的干粉气溶胶并且将所述气雾剂递送至患者的至少口腔或鼻子。 在另一个实施例中，吸入器包括人力可压缩部件，其可操作以在约1-40psi的压力下在聚合物压力释放阀的出口处排出空气脉冲; 以及接收面罩，所述接收面罩与可压缩部件的出口连通并且可操作以将干粉气溶胶递送到患者的至少口腔或鼻子。 在没有电力和电路以及预加压推进剂气体的情况下进行向患者输送干粉药物制剂的方法。 合适的干粉药物制剂可以包含肌醇和/或麦芽糖糊精作为载体和活性成分如疫苗或siRNA。